In summary, we report a previously unrecognized PTM and function of HNF1B in ccRCC, and provide a potential drug and strategy for clinical treatment of ccRCC by targeting HNF1B-YAP axis. This evidence concerns the gene HNF1B and nonpapillary renal cell carcinoma.